A Phase 3, Prospective, Multicenter, Double-Blind, Randomized, Controlled, Adaptive Study To Demonstrate The Safety And Efficacy Of DEFENCATH® In Reducing Central Line-Associated Bloodstream Infections (CLABSIs) In Adult Participants Receiving Total Parenteral Nutrition (TPN) Via Central Venous Catheter (CVC)
Latest Information Update: 12 Sep 2025
At a glance
- Drugs Citrate/heparin/taurolidine (Primary) ; Heparin
- Indications Catheter infections
- Focus Registrational; Therapeutic Use
- Sponsors CorMedix
Most Recent Events
- 15 Jul 2025 Planned number of patients changed from 140 to 200.
- 06 May 2025 According to a CorMedix Inc media release, status changed from not yet recruiting to recruiting.
- 06 May 2025 According to a CorMedix Inc media release, the company has commenced this study and the first site is operational and actively screening patients.